This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Goldman Sachs Remains a Hold on Pfizer (PFE)

Tipranks - Tipranks - Thu Nov 5, 8:10AM CST

In a report released today, Asad Haider from Goldman Sachs maintained a Hold rating on Pfizer, with a price target of $28.00.

According to TipRanks, Haider is a 5-star analyst with an average return of 26.9% and an 80.95% success rate. Haider covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and BioNTech SE.

In addition to Goldman Sachs, Pfizer also received a Hold from Citi’s Geoff Meacham in a report issued today. However, on the same day, Scotiabank maintained a Buy rating on Pfizer (NYSE: PFE).

See Insiders’ Hot Stocks on TipRanks >>

Based on Pfizer’s latest earnings release for the quarter ending September 27, the company reported a quarterly revenue of $16.58 billion and a net profit of $3.24 billion. In comparison, last year the company earned a revenue of $16.65 billion and had a net profit of $3.54 billion

Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PFE in relation to earlier this year. Most recently, in August 2026, JENNIFER B. DAMICO, the SVP & Controller of PFE sold 3,278.00 shares for a total of $83,261.20.

Read More on PFE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Market data provided by Barchart. Exchange delay details and data provider terms here. Information may be delayed, is provided 'as is' and is solely for informational purposes, and not for trading, investment or advice.